Pharmaceuticals, Biotechnology and Life Sciences
Novartis has gotten new evidence from the CHAMP-HF registry comparing Entresto patients to patients not taking Entresto, which showed that…
Novartis has announced a new post hoc analysis of the pivotal Phase III heart failure study, PARADIGM-HF, which showed that…
New analysis shows Novartis’ Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes. Novartis said on Saturday the new post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced ejection fraction (HFrEF) patients who also had diabetes.
European Commission has approved Switzerland-based Novartis’ Entresto tablets for treating adult patients with symptomatic chronic heart failure with reduced ejection fraction.
Switzerland-based Novartis has today appointed Dr. James E. Bradner, physician-scientist from Dana-Farber Cancer Institute and Harvard Medical School, as President of the…
Novartis announced on September 18 that Swissmedic has approved Entresto (sacubitril/valsartan), previously known as LCZ696, to reduce the risk of cardiovascular…